Form D · Biotechnology
Entact Bio, Inc.
Watertown, MA · CIK 0002008244
Offering snapshot reported Jun 3, 2026 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 3, 2026 | Initial | $9,999,997 | No comparison | 7 | SEC filing |
| May 15, 2024 | Amendment | $40,321,700 | $421,701vs Jan 31, 2024 | 7 | SEC filing |
| Jan 31, 2024 | Initial | $39,899,999 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586026
Source: Form D, filed Jun 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anna French | Director |
| Richard Gaster | Director |
| Alon Lazarus | Director |
| Pini Orbach | Director |
| Victoria Richon | Director, Executive, Promoter |
| Andrew Sinclair | Director |
| Owen Smith | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
65 Grove Street, Suite 303
Watertown, MA, 02472
Watertown, MA, 02472